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Background In patients with chronic heart failure, there is a positive linear relationship
between skeletal muscle mass (SMM) and peak oxygen consumption ( _VO2peak); an
independent predictor of all-cause mortality. We investigated the association
between SMM and _VO2peak in patients with coronary heart disease (CHD) without a
diagnosis of heart failure.
Methods Male patients with CHD underwent maximal cardiopulmonary exercise
testing and dual X-ray absorptiometry assessment. _VO2peak, the ventilatory anaero-
bic threshold and peak oxygen pulse were calculated. SMM was expressed as
appendicular lean mass (lean mass in both arms and legs) and reported as skeletal
muscle index (SMI; kg m2), and as a proportion of total body mass (appendicu-
lar skeletal mass [ASM%]). Low SMM was defined as a SMI <726 kg m2, or
ASM% <2572%. Five-year all-cause mortality risk was calculated using the Calibre
5-year all-cause mortality risk score.
Results Sixty patients were assessed. Thirteen (217%) had low SMM. SMI and ASM%
correlated positively with _VO2peak (r = 0431 and 0473, respectively; P<0001 for
both). SMI and ASM% predicted 163% and 129% of the variance in _VO2peak,
respectively. SMI correlated most closely with peak oxygen pulse (r = 058;
P<0001). SMI predicted 403% of peak _VO2/HR variance. ASM% was inversely
associated with 5-year all-cause mortality risk (r = 0365; P = 0006).
Conclusion Skeletal muscle mass was positively correlated with _VO2peak in patients
with CHD. Peak oxygen pulse had the strongest association with SMM. Low
ASM% was associated with a higher risk of all-cause mortality. The effects of exer-
cise and nutritional strategies aimed at improving SMM and function in CHD
patients should be investigated.
Introduction
Peak oxygen uptake ( _VO2peak), measured by a maximal car-
diopulmonary exercise test (CPET) represents the upper limit
of aerobic capacity. A low _VO2peak is associated with the loss
of independence in older individuals (Shephard, 2009) and
increased all-cause and cardiovascular mortality in patients
with coronary heart disease (CHD) (Keteyian et al., 2008).
The physiological factors that limit _VO2peak are summarized
by the Fick equation (Bassett & Howley, 2000; Poole et al.,
2012; Lundby et al., 2017):
_VO2peak ¼ cardiac output  ða vO2 diffÞ
Where cardiac output is the product of heart rate (HR) and
stroke volume (SV), and avO2 diff is the difference between
arterial and venous O2 content, representing muscle O2 extrac-
tion. In healthy individuals, _VO2peak is limited centrally; maxi-
mum cardiac output limits O2 delivery to the exercising
muscle at the rate that it is required for aerobic resynthesis of
ATP (Bassett & Howley, 2000; Lundby et al., 2017). However,
in patients with chronic heart failure (CHF), a cascade of
events alters peripheral muscle physiology. These include,
reduced skeletal muscle oxidative enzyme activity, reduced
mitochondrial density, decreased perfusion matching with
oxidative muscle fibres (Poole et al., 2012) and decreased
skeletal muscle mass (Cicoira et al., 2001). Consequently, the
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peripheral muscle may become the primary limitation to
_VO2peak (Clark et al., 1996; Shelton et al., 2010; Poole et al., 2012).
As CHF worsens, skeletal muscle mass (Collamati et al.,
2016) and _VO2peak decline (Piepoli et al., 2006; F€ulster et al.,
2013). However, this relationship has not yet been reported
in patients with CHD. Around a quarter of patients with CHD
have low muscle mass and function (sarcopenia) (Harada
et al., 2016), compared with only 10% of adults older than
60 years (Shafiee et al., 2017). Patients with CHD are com-
monly physically inactive which, together with progression of
the underlying CHD, may exacerbate loss of muscle mass.
Patients with CHD who experience a marked loss of skeletal
muscle mass may have a reduced _VO2peak and consequently
higher risk of early mortality. Identifying the relationship
between skeletal muscle mass and _VO2peak in patients with
CHD may be important so that preventative exercise and
nutritional interventions can be developed.
We aimed to describe the association between skeletal mus-
cle mass and _VO2peak in male patients with CHD. We also
assessed the relationship between skeletal muscle mass and
other potentially important variables: peak oxygen pulse (peak
_VO2/HR) (Laukkanen et al., 2006), ventilatory anaerobic
threshold (VAT) (Gitt et al., 2002), _VE/ _VCO2 slope (Van de
Veire et al., 2006), N-terminal pro B-type Natriuretic Peptide
(NT-proBNP) (Omland et al., 2007) and CALIBER 5-year all-
cause mortality risk (Rapsomaniki et al., 2014).
Methods
Study design
Data for this cross-sectional study included baseline measure-
ments taken from male patients enrolled in the Cardiovascular
and cardiorespiratory Adaptations to Routine Exercise-based
Cardiac Rehabilitation (CARE CR) study (Nichols et al., 2018).
Ethical approval was obtained from the Humber Bridge NHS
Research Ethics Committee – Yorkshire and the Humber (13/
YH/0278). Study procedures conform to the declaration of
Helsinki 1964.
The study protocol for CARE CR has previously been
reported (Nichols et al., 2018). Briefly, clinically stable male
patients who had recently been discharged from hospital fol-
lowing an admission for stable angina, myocardial infarction
(MI), coronary artery bypass graft (CABG) surgery or elective
percutaneous coronary intervention (PCI) were recruited.
Patients were asked to attend the research laboratory having
not participated in strenuous exercise within the previous
24 h. Written informed consent was obtained prior to con-
ducting any investigations.
Resting measurements
Resting HR and left arm brachial blood pressure were taken at
the end of 15 min semi-supine rest using a 12-lead ECG (GE
Healthcare, Buckinghamshire, UK) and an ECG-gated
automated blood pressure cuff (Tango, SunTech Medical, Eyn-
sham, UK). Stature (cm) was measured using a Leicester
Height Measure (SECA, Birmingham, UK). Waist circumfer-
ence measurements were taken 1 cm above the iliac crest, and
hip measurements were taken from the widest aspect of the
buttocks. Both measurements were recorded in cm, and the
ratio of the two was calculated to determine waist-to-hip cir-
cumference ratio (ACSM 2017).
A 2D echocardiogram was used to determine left ventricular
(LV) function. LV ejection fraction (LVEF) was calculated
using Simpson’s method from measurements of end-diastolic
and end-systolic volumes on apical four- chamber and two-
chamber 2D views, following the guidelines of Lang and
colleagues (Lang et al., 2015). LV systolic dysfunction was
diagnosed if LVEF was ≤45%.
Body composition
Body composition was determined using dual X-ray absorp-
tometry [DEXA] (Lunar iDXA, 255 GE Healthcare). Total body
mass (kg), lean body mass (kg) and total fat (%) were deter-
mined using the Lunar iDXA’s integrated software. BMI
(kg m2) was calculated using DEXA-derived total body mass.
Appendicular lean mass (ALM; total lean mass in both arms
and legs) was calculated (kg) and indexed to derive skeletal
muscle index (SMI; measured in kg m2). ALM was also
reported as a percentage of total body mass (appendicular
skeletal mass; ASM%). Low skeletal muscle mass was defined
as an SMI of <726 kg m2 as recommended by international
consensus guidelines (Cruz-Jentoft et al., 2010). A low ASM%
was defined as <2572% (Levine & Crimmins, 2012). This
approach may be more appropriate for patients who are over-
weight/obese and have a higher absolute skeletal muscle mass,
but low skeletal muscle mass relative to their total body mass.
Maximal cardiopulmonary exercise test
The cardiopulmonary exercise testing adhered to established
guidelines and recommendations (American Thoracic Society/
American College of Chest Physicians 2003; Balady et al.,
2010; Nichols et al., 2015; Taylor et al., 2015) and was per-
formed using the modified Bruce treadmill protocol (Bruce
et al., 1973) (GE Healthcare). A 12-lead ECG was monitored
continuously throughout the test. An ECG-gated automated BP
measurement was recorded at the start of the test and at the
second minute of each test stage until the end of the test. Rat-
ing of perceived exertion (RPE) scores (6-20) was recorded at
peak exercise (Borg, 1982). Breath-by-breath metabolic gas
exchange data were collected using an Oxycon Pro metabolic
cart (Jaeger, Hoechburg, Germany). _VO2peak was defined as
the mean _VO2 (ml) over the last 30 s of the test. _VO2peak was
also adjusted for body mass (ml kg1 min1). The VAT was
analysed by two independent investigators using the V-slope
method (Beaver et al., 1986) with data averaged over the mid-
dle five of seven consecutive breaths. The VAT was reported
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in ml, and standardized to patient body mass
(ml kg1 min1). _VO2/HR (ml per beat) and _VE/ _VCO2
slope were calculated as previously described (Nichols et al.,
2015, 2018).
Pulse wave velocity
Pulse wave velocity (PWV) between the brachium and ankle
was measured (Vascular Explorer, Enverdis GmbH, D€usseldorf,
Germany) after 15 min of semi-supine rest (torso elevated
45°) in a quiet temperature controlled room (21°C). A blood
pressure cuff was placed proximally to the left cubital fossa
(brachial artery) and another placed proximally to the medial
malleolus. Photoplethysmographic sensors were placed on the
patients left index finger and left hallux. Oscillations in the
pulse waves alter the volume of the blood pressure cuff and
are converted to a PWV. A shorter PWV (ms) indicates more
severe arterial stiffness and/or worse peripheral vascular
health. The reproducibility of PWV measurement at a single
time point has been shown to be good (intraclass correlation
072–086) (Sutton-Tyrrell et al., 2001).
Blood samples
Resting venous blood samples were collected in ethylenedi-
aminetetraacetic acid (EDTA), potassium oxalate and serum
separating tubes (SST). EDTA and potassium oxalate tubes
were spun in a refrigerated (4°C) centrifuge at 3000 revolu-
tions per min, for 15 min immediately after the blood draw.
Samples collected in SST tubes were allowed to clot for
30 min prior to being centrifuged under the same conditions.
Haematocrit and haemoglobin concentrations, neutrophil and
lymphocyte count, and NT-proBNP were analysed using a reg-
istered National Health Service (NHS) pathology laboratory
(Castle Hill Hospital, Hull). All samples not analysed on the
day of collection were stored in a 80°C freezer. The ABX
Pentra 400 biochemistry auto analyser (Horiba, Montpellier,
France) was used to analyse serum plasma glucose, and high
sensitivity C-reactive protein (hs-CRP) in duplicate. Calibration
and quality controls were conducted in accordance with man-
ufacturer’s guidelines.
Prognosis – Calibre 5-year all-cause mortality risk
Five-year risk of all-cause mortality was calculated for each
patient using the comprehensive online (https://www.caliber
research.org/model) Calibre 5-year risk score (Rapsomaniki
et al., 2014). The Calibre risk score has been developed in a
population of 100 000 patients with CHD. The model has
good calibration and discrimination in internal and external
validation (C-Index 0811) for all-cause mortality. Impor-
tantly, the model does not include any fitness measurements
in its calculation. Five-year risk of all-cause mortality was
reported as a percentage. The variables included in the Calibre
score are shown in Table 1.
Statistical analysis
Statistical analysis was performed using SPSS version 22 (IBM,
New York, NY, USA). The distribution of the data were
assessed visually and using the Shapiro–Wilk test. Categorical
data are reported as percentages. Continuous normally dis-
tributed variables are displayed as mean with 95% confidence
intervals (95% CI) or standard deviation () where specified.
Non-normally distributed data are displayed as median
(range). Pearson’s (normally distributed), Spearman’s correla-
tions (non-normally distributed) and age-adjusted partial cor-
relations were used to assess the relationship between indices
of skeletal muscle mass and variables of interest. An r value of
<025, 026–050, 051–075, and, >075 were considered
weak, moderate, fair and strong associations, respectively
(Berg & Latin, 2008). Scatter plots of partial correlations were
constructed using the residuals of the independent skeletal
muscle indices and dependent variables. Where a variable was
significantly associated with SMI or ASM%, receiver operating
characteristic (ROC) curves were used to investigate the sensi-
tivity and specificity of predicting low skeletal muscle mass.
Patients with a low skeletal muscle mass (SMI <726 Kg m2
or ASM% <2572%) were treated as the dichotomous ‘state-
variable’ for the ROC curve. Statistical significance was set at
P = 005.
Up to six dependent variables with the strongest, significant
age-adjusted partial correlations were selected for inclusion
within separate stepwise multivariate regression models. The
main outcome variables selected were _VO2peak, VAT, peak
_VO2/HR, CPET duration, Calibre 5-year all-cause mortality
risk and NT-proBNP.
Results
Sixty male patients (aged, 621  100 years; BMI,
288  37 kg m2) were recruited. Patient characteristics,
comorbidities and medications are reported in Tables 2, 3 and
4, respectively. Fifteen patients (250%) had sustained a ST-
elevation MI, 19 (317%) a non-ST-elevation MI, 16 (267%)
underwent elective PCI, 6 (100%) CABG and 4 (67%) had
exertional angina. Comorbidities are shown in Table 3. Med-
ian time from cardiac event to baseline assessment was
54 days (range 22–220 days). Mean resting HR was
82 bpm  14 bpm. Mean resting systolic and diastolic blood
pressure was 127  17 mmHg and 58  9 mmHg, respec-
tively. Four patients (66%) had a LVEF <45%, ten (167%)
had an NT-proBNP >400 pg l1 and one (17%) had an NT-
proBNP >2000 pg l1. The proportion of patients with low
skeletal muscle mass was 167% by SMI and 117% by ASM%.
However, only four patients had both a low SMI and ASM%,
meaning that 13 (217%) had a low SMI or ASM%.
Correlations between ALM, SMI, ASM% and dependent vari-
ables of interest are presented in Table 5. The associations
between ALM, SMI and _VO2peak (ml) were r = 0566
(P<0001) and r = 0473 (P<0001), respectively. The
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association between ASM% and _VO2peak (ml kg
1 min1) was
r = 0420 (P = 0001). The strongest associations between
indices of skeletal muscle mass and secondary outcome
measures were observed between; ALM and peak _VO2/HR
(r = 0633; P<0001), SMI _VO2/HR (r = 0575; P<0001)
and ASM% and _VO2peak [ml kg
1 min1] (r = 0431;
P<0001). CPET variables that were significantly associated
with ALM, SMI and ASM% are shown in Fig. 1. ASM% was
the only method of characterizing skeletal muscle mass result-
ing in a significant association with PWV, NT-proBNP and
Calibre 5-year all-cause mortality risk.
ROC curve analysis
Receiver operating characteristic curve analysis was conducted
on variables that were significantly associated with measure-
ments of SMI or ASM%. The area under the curve (AUC) for
each prognostic variable is shown in Table 6. For SMI, peak
_VO2/HR had the greatest predictive capacity (AUC = 0767;
P = 0008). Values <133 ml per beat was predictive of a low
SMI. When patients with a low SMI or ASM% were combined,
peak _VO2/HR AUC was 0764 (P = 0004). A peak _VO2/HR
<143 ml per beat was most predictive of patients with a low
SMI or ASM%. Patients with a NT-proBNP >1125 pg l1, a Cal-
ibre risk score >30% or a modified Bruce treadmill duration
<17 min 43 s were also more likely to have a low ASM%.
Table 2 Patient characteristics.
Variable Mean (SD)
Age (Years) 631 (100)
BMI (kg m2) 288 (37)
ALM (kg) 248 (40)
SMI (kg m2) 83 (11)
ASM% 291 (25)
Body fat% 355 (93)
Waist/Hip ratio 098 (006)
_VO2peak (ml kg
1 min1) 240 (56)
_VO2peak (ml) 20793 (5526)
_VO2peak Lean (ml kg
1 min1) 385 (83)
VAT (ml kg1 min1) 172 (51)
VAT (ml) 14819 (4524)
VAT Lean (ml kg1 min1) 278 (76)
Peak _VO2/HR (ml per beat) 155 (33)
Peak HR (bpm) 134 (20)
_VE/ _VCO2 slope 343 (60)
CPET duration (s) 8266 (1938)
LVEF (%) 543 (67)
Calibre 5-year risk (%) 83 (70)
NT-proBNP (pg l1) 1745 (114–27350)
hs-CRP (mg l1) 23 (30)
Glucose (mmol l1) 61 (20)
BMI, body mass index; ALM, appendicular lean mass; SMI, skeletal
muscle index; ASM%, appendicular skeletal mass; _VO2peak, peak oxy-
gen uptake; VAT, ventilatory anaerobic threshold; _VO2/HR, oxygen
pulse; HR, heart rate; bpm, bats per minute; _VE/ _VCO2 slope, ventila-
tory efficiency with respect to carbon dioxide elimination; CPET, car-
diopulmonary exercise test; LVEF, left ventricular ejection fraction;
NT-proBNP, N-terminal pro B-type natriuretic peptide; hs, high sensi-
tivity.
Table 3 Patient comorbidities (Frequency).
Comorbidity All patients
Hypertension (%) 27 (450)
Diabetes (%) 11 (183)
COPD (%) 2 (33)
Hyperlipidaemia (%) 38 (633)
Hypothyroidism 5 (91)
Previous PCI (%) 13 (217)
Previous MI (%) 14 (234)
Previous CABG (%) 4 (67)
Previous cardiac valve surgery (%) 1 (17)
Previous CVA (%) 6 (100)
Previous Cancer 8 (133)
COPD, chronic obstructive pulmonary disease; PCI, percutaneous coro-
nary intervention; MI, myocardial infarction; CABG, coronary artery
bypass graft; CVA, cerebrovascular accident.
Table 4 Patient medications (Frequency).
Medications All patients
Aspirin (%) 58 (967)
Clopidogrel (%) 16 (267)
Ticagrelor (%) 33 (550)
Beta-Blockers (%) 54 (900)
ACE Inhibitors (%) 38 (633)
Statins (%) 57 (950)
Diuretics (%) 5 (83)
Nitrates (%) 13 (217)
GTN (%) 54 (900)
ACE, angiotensin converting enzyme; GTN, glyceryl trinitrate.
Table 1 Variables included in the CALIBER 5-year risk score.
Categorical variables Continuous variables
Sex Age
Belongs to most deprived quintile Total cholesterol
CAD diagnosis and severity HDL
Interventions (last 6 months) Heart rate
Smoking status Creatinine
Hypertension/BP lowering medication White cell count
Diabetes Haemoglobin
Heart failure
Peripheral arterial disease
Atrial fibrillation
Stroke
Chronic renal disease
COPD
Cancer
Chronic liver disease
Depression
Anxiety
CAD, Coronary Artery Disease; BP, Blood Pressure; COPD, Chronic
Obstructive Pulmonary Disease; HDL, High-density Lipoprotein.
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Multivariate regression
Appendicular lean mass and age (both P<0001) were
independent predictors of _VO2peak (ml) and VAT (ml). For
_VO2peak, these variables explained 588% of variance. For VAT
348% was explained. ALM alone accounted for 434% and
239% of variance for _VO2peak and VAT, respectively. ALM
was the only significant predictor of peak _VO2/HR (P<0001),
accounting for 498% of variance.
Skeletal muscle index and age were independent predictors
of _VO2peak and the VAT (ml). For _VO2peak, 525% of variance
was explained by SMI and age, with SMI accounting for
163%. For VAT, 358% of variance was explained by SMI and
age. About 121% of variance was explained by VAT alone.
Interestingly, only SMI was an independent predictor for peak
_VO2/HR. 403% of variance was accounted for by _VO2/HR.
Similar to SMI, ASM% and age (both P<0001) were inde-
pendent predictors of _VO2peak and VAT, standardised to body
Figure 1 Partial correlations between appendicular lean mass and _VO2peak (a), VAT (b), and peak _VO2/HR (c). Panels d to f show partial correla-
tions between skeletal muscle index and _VO2peak (d), VAT (e) and peak _VO2/HR (f). Panels G to H show partial correlations between appendicular
skeletal mass and _VO2peak (g), VAT (h), and total CPET Duration (i). _VO2peak, peak oxygen uptake; VAT, ventilatory anaerobic threshold; _VO2/HR,
oxygen pulse; CPET, cardiopulmonary exercise test. * = Significant; + = Low muscle mass when defined using skeletal muscle index
(<726Kg m2); ◊ = Low muscle mass when defined using appendicular skeletal mass (<2572%); Δ = Low muscle mass when using either
skeletal mass or appendicular skeletal mass.
Table 6 Area under the curve for variables associated low skeletal muscle mass (95% confidence intervals).
Variable
SMI ASM% SMI & ASM%
Area under the curve P-value Area under the curve P-value Area under the curve P-value
_VO2peak (ml) 0649 (0478–0820) 0139 – – 0675 (0527–0823) 0055
_VO2peak (ml kg
1 min1) – – 0726 (0510–0943) 0053 0615 (0430–0810) 0206
Peak _VO2/HR (ml per beat) 0767 (0613–0921) 0008* – – 0764 (0632–0895) 0004*
VAT (ml) 0594 (0399–0789) 0351 – – 0620 (0455–0786) 0187
VAT (ml kg1 min1) – 0679 (0454–0904) 0126 0561 (0368–0755) 0501
CPET duration (s) – 0744 (0510–0943) 0037* 0648 (0466–0830) 0104
Calibre 5-year risk (%) – 0805 (0600–100) 0009* 0383 (0191–0574 0202
NT-proBNP (pg l1) – 0759 (0511–100) 0027* 0623 (0420–0825) 0178
SMI, skeletal muscle index; ASM%, appendicular skeletal mass; _VO2peak, peak oxygen uptake; _VO2/HR, oxygen pulse; VAT, ventilatory anaerobic
threshold; CPET, cardiopulmonary exercise test; NT-proBNP, N-terminal pro B-type natriuretic peptide.
*Significant.
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mass (ml kg1 min1). 388% of _VO2peak (ml kg1 min1)
and 178% of VAT (ml kg1 min1) variance was accounted
for by ASM% and age. ASM% alone accounted for 129% of
_VO2peak variance, compared to 63% for VAT. Age and ASM%
were also independent predictors of NT-proBNP (P<0001)
with age accounting for 205% of NT-proBNP variance and
ASM% accounting for 72% (combined model; 272%). ASM%
accounted for 94% of total Calibre 5-year all-cause mortality
risk score variance (P<0001).
Discussion
To our knowledge, this is the first study to investigate the
relationship between skeletal muscle mass and _VO2peak in
patients with CHD. We identified that a lower skeletal muscle
mass was associated with a lower _VO2peak, an observation pre-
viously reported in patients with CHF (Cicoira et al., 2001).
We also investigated the relationship between other important
prognostic indicators, including peak _VO2/HR. Our data sug-
gest that skeletal muscle mass may be more closely associated
with peak _VO2/HR, rather than _VO2peak. Similar to previously
reported data in patients with CHD (Harada et al., 2016), we
found that more than one-fifth of patients had a low skeletal
muscle mass; a higher proportion than reported among adults
over the age of 60 years (10%) (Shafiee et al., 2017). A lower
skeletal muscle mass was associated with a higher 5-year all-
cause mortality risk.
Peak oxygen uptake
Sarcopenia and/or a low muscle mass are associated with
increased mortality risk (Cawthon et al., 2007) and difficulties
performing daily activities (Janssen, 2006). A low _VO2peak is
also associated with a higher mortality risk (Keteyian et al.,
2008) and difficulties performing daily activities (Shephard,
2009). Consistent with data reported on patients with CHF
(r = 046 to r = 070) (Cicoira et al., 2001; Piepoli et al.,
2006), we found that ALM was positively associated with
_VO2peak (r = 0566). Although dependent on the methods
used to scale _VO2peak, this relationship was maintained when
ALM was standardized to stature (SMI; r = 0473) and body
mass (ASM%; r = 431). However, whilst ALM (434%), SMI
(163%) and ASM% (129%) were independent predictors of
_VO2peak, we were unable to replicate the same predictive
strength (54-65%) reported by Cicoira, et al. in non-cachexic
patients with CHF. This may be because patients with CHF
can have severe skeletal muscle abnormalities (Clark et al.,
1996; Vescovo et al., 1996; Piepoli et al., 2010; Poole et al.,
2012) that limit exercise tolerance as a consequence of the
disease (Shelton et al., 2010). Given that CHD represents an
earlier stage of cardiovascular dysfunction than CHF, skeletal
muscle abnormalities may occur at an earlier stage of cardio-
vascular dysfunction. Skeletal muscle mass may therefore play
a greater role in limiting _VO2peak among patients with CHF,
compared with patients who have CHD. Our observation may
suggest that adverse changes in skeletal muscle mass and qual-
ity associated with cardiovascular dysfunction exist on a con-
tinuum. If this were true, early optimization strategies that
target peripheral muscle in addition to cardiac function may
be important for disease prevention.
Peak _VO2/HR was most closely associated with indices of
skeletal muscle mass. ALM and SMI separately accounted for
498% and 403% of the variance in peak _VO2/HR, respec-
tively. These indices of skeletal muscle mass not only had a
stronger association with peak _VO2/HR (r = 0575 to
r = 0633) compared to _VO2peak (r = 0566), but also had the
largest AUC (0767; 95% CI 0613–0921; P = 0008). Unlike
_VO2peak, peak _VO2/HR had good sensitivity and specificity for
detecting patients with a low SMI. A threshold of 133 ml per
beat was identified as the point below which, patients were
more likely to have a low SMI (726 kg m2). Simple rear-
rangement of the Fick equation means that peak _VO2/HR
becomes independent of HR; a factor that we (r = 0042,
0073, 0026; P>005 for all) and others (Horwich et al.,
2009; Piepoli et al., 2017) have found to be unrelated to
skeletal muscle. Instead, reported peak _VO2/HR characterizes
SV and a-vO2 difference (peripheral O2 extraction) which may
explain why it appears to be more closely related to skeletal
muscle mass than _VO2peak, in patients with CHD. However,
whilst skeletal muscle mass has previously been identified as
an independent predictor of peak _VO2/HR (74%) in hyper-
tensive men and women (Lim et al., 2005), the association
between peak indices of skeletal muscle mass and peak _VO2/HR
in our study was smaller [403–498%] (Lim et al., 2005).
Nonetheless, this is an interesting finding and should be further
explored in a larger cohort.
The weaker relationship between indices of skeletal muscle
mass and peak _VO2/HR observed in our study may indicate
that patients with CHD have a different physiological response
to maximal exercise, compared to patients with hypertension.
Under normal circumstances, _VO2/HR rises progressively
throughout an incremental exercise test until it reaches a pla-
teau associated with normal physiological limitation to exer-
cise (Whipp et al., 1996). However, in patients with CHD,
_VO2/HR may prematurely decrease during incremental exer-
cise due to ischaemia-induced myocardial wall-motion abnor-
malities which cause a reduction in SV (Belardinelli et al.,
2003). This is thought to occur prior to ST-segment changes
detected using electrocardiogram, or symptoms of angina
(Nesto & Kowalchuk, 1987). If myocardial blood flow is not
restored through surgical or medical intervention, _VO2/HR
would be lower than expected at peak exercise and may atten-
uate the association between _VO2/HR, a-vO2 difference and
skeletal muscle mass. Alternatively, a low peak _VO2/HR may
indicate greater cardiac dysfunction and consequently, more
severe skeletal muscle abnormalities. However, whilst we can-
not confirm either of these scenarios, peak _VO2/HR was a
better predictor of SMI than any other measured variable,
including _VO2peak, the gold-standard measurement of aerobic
exercise capacity. Formal screening for sarcopenia in patients
© 2018 The Authors. Clinical Physiology and Functional Imaging published by John Wiley & Sons Ltd on behalf of Scandinavian Society of Clinical
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who are incidentally found to have a low peak _VO2/HR may
be beneficial.
Prognostically important associations with skeletal
muscle mass
Although SMI was associated with peak _VO2/HR, ASM% was
not. However, ASM% was inversely associated with prognosti-
cally important variables including; _VO2peak, PWV, 5-year all-
cause mortality risk, a higher NT-proBNP and, body fat per-
centage even when controlling for age. Although not specifi-
cally investigated by our study, the faster PWV speeds
observed among patients with a lower SMI indicates more sev-
ere arterial stiffness and greater abnormalities in peripheral
cardiovascular health, something reported among patients
with CHF (Poole et al., 2012). Furthermore, the higher NT-
proBNP values reported among patients with a lower ASM%
suggests more advanced CHD, or the early development of
CHF which may exacerbate the loss of skeletal muscle mass
(Collamati et al., 2016). The association between higher body
fat percentage and relative lower skeletal muscle mass may
also indicate the onset of sarcopenic obesity, fat infiltration of
skeletal muscle and therefore reduced muscle quality (Narici
& Maffulli, 2010).
Strengths and weaknesses
This is the first study to use gold-standard measurement tech-
niques (DXA and CPET) to investigate the relationship
between low skeletal muscle mass and reduced aerobic exer-
cise capacity in CHD patients. In addition, this study included
a representative cohort of male patients with CHD and the sta-
tistical methods employed controlled for several variables that
are commonly associated with reduced skeletal muscle mass
and aerobic exercise capacity. However, this study has limita-
tions; first, we did not assess muscle function, which meant
that we could not report the prevalence of sarcopenia in our
cohort. Second, our findings in our male only cohort may not
be relevant to females with CHD. In addition, the sample size
used in this population was relatively small. Finally, whilst the
associations identified in our cross-sectional cohort study are
interesting, a prospective long-term follow-up study is
required. This would help to determine whether progression
of CHD confers with reduced skeletal muscle mass and
whether this relates to prognostically important variables and/
or the development of CHF.
Conclusion
We found a high incidence of low skeletal muscle mass in
our cohort of patients with CHD. When standardized to body
mass (ASM%), low skeletal muscle mass conferred a higher
predicted risk of all-cause mortality. Low skeletal muscle mass
was associated with a low _VO2peak in patients with CHD;
however, the relationship was complex and dependent on the
method used to scale skeletal muscle mass and _VO2peak. Inter-
estingly, our data show that there was a stronger association
between SMI and peak _VO2/HR. The relationship between
low skeletal muscle mass, prognostic indices and aerobic fit-
ness suggests that adverse changes in skeletal muscle mass
may be initiated before the diagnosis or development of CHF.
These findings may highlight a need for preventative exercise
and nutritional strategies to improve skeletal muscle mass and
quality in patients with CHD.
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